EpiVax, Inc., Providence, RI, USA; Center for Vaccines and Immunology, University of Georgia, USA.
Center for Drug Evaluation and Research, FDA, White Oak, MD, USA.
Clin Immunol. 2021 Mar;224:108661. doi: 10.1016/j.clim.2020.108661. Epub 2021 Jan 4.
Identification of T cell epitopes that are recognized by Tregs may elucidate the relative contributions of thymic Tregs and induced Tregs to control of autoimmune diseases and allergy. One such T regulatory cell epitope or 'Tregitope', derived from blood Factor V, is described here. Tregs responding to Tregitope FV621 are potent suppressors of CD4+ T effector responses to Tetanus Toxoid in an in vitro bystander suppression assay, strongly inhibit proliferation of effector CD8+ T cells, down-modulate CD86 and HLA DR on antigen-presenting cells, and enhance expression of granzyme B in Tregs. Tregitope FV621 also suppresses anti-OVA immune responses in vivo. The immunomodulatory effect of Tregitope FV621 is enhanced when conjugated to albumin, suggesting that the short half-life of Tregitope peptides can be prolonged. The in silico tools used to prospectively identify the FV Tregitope described here, when combined with in vitro /in vivo validating assays, may facilitate future Tregitope discoveries.
鉴定 T regs 识别的 T 细胞表位可能阐明胸腺 Tregs 和诱导性 Tregs 对控制自身免疫性疾病和过敏的相对贡献。本文描述了一种源自血液因子 V 的调节性 T 细胞表位或“Tregitope”。在体外旁观者抑制试验中,对 Tregitope FV621 有反应的 Tregs 是破伤风类毒素 CD4+ T 效应应答的有效抑制剂,强烈抑制效应 CD8+ T 细胞的增殖,下调抗原呈递细胞上的 CD86 和 HLA DR,并增强 Tregs 中颗粒酶 B 的表达。Tregitope FV621 还抑制体内抗 OVA 免疫反应。当与白蛋白缀合时,Tregitope FV621 的免疫调节作用增强,表明 Tregitope 肽的半衰期短,可以延长。本文描述的用于前瞻性鉴定 FV Tregitope 的计算工具,结合体外/体内验证试验,可能有助于未来的 Tregitope 发现。